Phase 3, Multicenter Open‐Label study to investigate the efficacy of elbasvir and grazoprevir fixed‐dose combination for 8 weeks in treatment‐naïve, HCV GT1b‐infected patients, with non‐severe fibrosis-Reference-Cited by-同舟云学术

Phase 3, Multicenter Open‐Label study to investigate the efficacy of elbasvir and grazoprevir fixed‐dose combination for 8 weeks in treatment‐naïve, HCV GT1b‐infected patients, with non‐severe fibrosis

Published:2020-06 Issue:8 Volume:40 Page:1853-1859
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Abergel Armand¹²^ORCID,Asselah Tarik³⁴^ORCID,Mallat Arianne⁵⁶,Chanteranne Brigitte¹^ORCID,Faure Frederic¹,Larrey Dominique⁷,Gournay Jerome⁸,Loustaud‐Ratti Veronique⁹,Di Martino Vincent¹⁰^ORCID,Fouchard‐Hubert Isabelle¹¹¹²,Pol Stanislas¹³,Bailly Francois¹⁴¹⁵,Samuel Didier¹⁶^ORCID,Tran Albert¹⁷,Dodel Marie¹,Andant Nicolas¹⁸,Lamblin Geraldine¹,Muti Leon¹,Reymond Maud¹,Teilhet Camille¹,Pereira Bruno¹⁸,Buchard Benjamin¹

Affiliation:

1. Service de médecine digestive et hépato‐biliaire CHU Estaing Clermont‐Ferrand France

2. UMR 6602 CNRS‐Sigma‐Université Clermont Auvergne Clermont‐Ferrand France

3. Department of Hepatology Université Paris DiderotSorbonne Paris CitéCRIUMR 1149Inserm Paris France

4. Department of Hepatology AP‐HP Hôpital Beaujon Clichy France

5. Department of Hepatology and Gastroenterology Hôpital Henri MondorAP‐HPINSERM Créteil France

6. Faculté de Médecine Université Paris‐Est Créteil France

7. Department of Hepatology Hôpital Saint EloiINSERM1183Montpellier University Montpellier France

8. Gastroenterology and Hepatology Department Institut des Maladies de l'Appareil Digestif University Hospital Nantes Nantes France

9. Department of Hepatology and Gastroenterology CHU LimogesINSERM U1248Université de Limoges Limoges France

10. Service d'Hépatologie CHRU Jean Minjoz and Université de Franche‐Comté Besançon France

11. Hepato‐Gastroenterology Department Angers University Hospital Angers France

12. HIFIH Laboratory, UPRES 3859, SFR 4208 Angers University Angers France

13. Department of Hepatology APHP Hôpital CochinUniversité Paris Descartes/INSERM U1223Institut Pasteur Paris France

14. Service d'Hépatologie et Gastroentérologie Hôpital de la Croix‐Rousse Lyon France

15. INSERM U1052Centre de Recherche en Cancérologie de Lyon Lyon France

16. AP‐HP Hôpital Paul‐Brousse Centre Hépato‐Biliaire Université Paris‐SudUMR‐S1193Université Paris‐Saclay, and Hepatinov Villejuif France

17. Department of Gastroenterology Université Côte d'AzurCHU de NiceINSERM, Centre Digestif Nice France

18. Biostatistics Unit Délégation Recherche Clinique & Innovation (DRCI) CHU Clermont‐Ferrand Clermont‐Ferrand France

Funder

Merck Sharp and Dohme

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/liv.14502

Reference37 articles.

1. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

2. Global epidemiology and genotype distribution of the hepatitis C virus infection

3. Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

4. Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection

5. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modern principles of etiotropic therapy for chronic hepatitis B and C;Russian Family Doctor;2023-01-18

2. Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study;Digestive and Liver Disease;2021-09

3. Screening, confirmation, and treatment rates of hepatitis C virus infection in a tertiary academic medical center in South Korea;Journal of Gastroenterology and Hepatology;2021-04-12

4. Virological Factors Associated with Failure to the Latest Generation of Direct Acting Agents (DAA) and Re-Treatment Strategy: A Narrative Review;Viruses;2021-03-08

5. Natural prevalence of NS3 gene resistance-associated substitutions (RASs) in patients with chronic hepatitis C from the state of Pará/Brazil;Virus Research;2021-01